An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy

BACKGROUND: For lung adenocarcinoma (LUAD) patients receiving platinum-based adjuvant chemotherapy (ACT), predictive signatures extracted from survival data solely are not directly associated with platinum response. Another limitation of reported signatures, commonly based on risk scores summarised...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Cancer
Hlavní autoři: Qi, Lishuang, Li, Yang, Qin, Yuan, Shi, Gengen, Li, Tianhao, Wang, Jiasheng, Chen, Libin, Gu, Yunyan, Zhao, Wenyuan, Guo, Zheng
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2016
Témata:
Translational Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5155365/
https://ncbi.nlm.nih.gov/pubmed/27855439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.370
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky